MARKET

SPTX

SPTX

SEAPORT THERAPEUTICS INC
NASDAQ
18.00
+0.28
+1.58%
After Hours: 18.00 0 0.00% 16:10 06/12 EDT
OPEN
17.78
PREV CLOSE
17.72
HIGH
18.50
LOW
17.51
VOLUME
99.62K
TURNOVER
--
52 WEEK HIGH
23.00
52 WEEK LOW
14.85
MARKET CAP
954.50M
P/E (TTM)
-1.7405
1D
5D
1M
3M
1Y
5Y
1D
3 Best Stocks to Buy Today, 6/9/2026, According to Top Analysts
TipRanks · 3d ago
Analysts Are Bullish on Top NA Stocks: Alamar Biosciences, Inc. (ALMR), Seaport Therapeutics, Inc. (SPTX)
TipRanks · 3d ago
Seaport Therapeutics: Buy Rating Reiterated on Advancing CNS Pipeline and Strong Cash Runway; $42 Price Target Unchanged
TipRanks · 3d ago
Buy Rating Reaffirmed on Seaport’s Advancing CNS Pipeline; $35 Price Target Maintained
TipRanks · 3d ago
Seaport Therapeutics Reports Wider Net Loss In Q1; Expects Phase 2b BUOY-1 Trial Data In H1,2027
NASDAQ · 4d ago
PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS REPORTS POSITIVE MULTIPLE-ASCENDING DOSE DATA FROM PHASE 1 PROOF-OF-CONCEPT TRIAL OF GLYPHAGO™ IN HEALTHY VOLUNTEERS
Reuters · 4d ago
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Barchart · 4d ago
Seaport Therapeutics, Inc. GAAP EPS of -$10.34
Seeking Alpha · 4d ago
More
About SPTX
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.

Webull offers Seaport Therapeutics stock information, including NASDAQ: SPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPTX stock methods without spending real money on the virtual paper trading platform.